

DAFTAR PUSTAKA

1. Weiner A. Drug Delivery System in Ophthalmic Application. In Yotio T, Clarck AF, Wav MB(ed) *Ocular Therapeutics*. USA. 2012. Elseiver. : 7-30
2. Gilger BC. Challenges in Ocular Pharmacokinetics, Pharmacodynamics, and Toxicology. In In Gilger BC(ed) *Methods in Pharmacology and Toxicity : Ocular Pharmacology and Toxicity*. New York .Humana Press. 2014:1-6
3. Cholkar K, Vadlapudi AD, Trinh HM, Mitra AK. Composition, Formulation, Pharmacology, Pharmacokinetics, and Toxicity of Topical, Periocular, and Intravitreal Ophthalmic Drugs. In Gilger BC(ed) *Methods in Pharmacology and Toxicity : Ocular Pharmacology and Toxicity*. New York. Humana Press. 2014: 91-98
4. Duval B, Kershner R. *Ophthalmic Medication and Pharmacology*. Boston. Slack Incorp. 2012 : 1-5
5. Cvenkel B, Stunf S, Kirbis IS, Flezaar MS. Symptoms and Sign of Ocular Surface Disease Related to Topical Medication in Patients with Glaucoma. *Clinical Ophthalmology*. 2015. Volume 9 : 625-631
6. Pinheiro R, Panfil C, Schrage N, Dutescu RM. The Impact Of Glaucoma Medication on Corneal Wound Healing. *Journal Of Glaucoma*. 2016. Volume 25 (1) : 122-127
7. D Agahan AL, Verde JE. Effects of Topical Timolol and Latanaprost by Tear Film Evaluation and Impression Citology. *Ophthalmology Case Report*.2017. Volume 1 (1) : 8-14
8. Kashkouli MB, Rezaee R, Nilforushan N, salimi S, Faroutan A, Joshaghani M. Topical Anti-Glaucoma Medication and Lacrimal Drainage System Obstruction. *Iranian Journal of Ophthalmology*.2008.Volume 20 (2) : 20-26
9. Seider N, Miller B, Beiran I. Topical Glaucoma Theraphy as a Risk Factor for Nasolacrimal Duct Obstruction. *American Journal of Ophthalmology*. 2008. Volume 145 (1) : 120-123
10. Pakdel F, Kashkouli MD. Lacrimal Drainage Obstruction Associated with Topical and Systemic Medication. *Journal Ophthalmology and Vision Research*. 2009. Volume 4(4) : 270-277
11. Hejkal TW, Camrass CB. Prostaglandin Analogs. In Netland PA(ed) *Glaucoma Medical Therapy : Principles and Management*. Second Edition. UK. Oxford University Press.2008 : 33-53
12. Pfeifer N, Thieme H. Prostaglandin Analogues. In Shaarawy TM, Sherwood MB, Hitching RA, Crowston JG (eds) *Glaucoma Medical Fiagnosis and Theraphy*. Second Editiom. Volume One. London. Elsevier Saunders. 2015 : 542-547
13. Hollo G, Aihara M, Alm A. Prostaglandin. In Weinreb RN, Araie M, Susanna R, Goldberg I, Migdal C, Liebmann (eds) *Medical Treatment of Glaucoma*. Amsterdam. Kugler Pub. 2010 : 74-86
14. Konstas AGP, Kozobolis V, Tsironi S, Makridaki I, Efremova R, Stewart WC. Comparison of the 24-Hour Intraocular Pressure-Lowering Effects of Latanoprost and Dorzolamide/Timolol Fixed Combination After 2 and 6 Month of Treatments. *Ophthalmology*. Volume 115. No 1. 2008 : 99-103

15. Varma, R, Hwang L, Grunden JW, Bean GW, Sultan MB. Assessing the Efficacy of Latanoprost vs Timolol Using an Alternate Efficacy Parameter : The Intervisit Intraocular Pressure Range. *America Journal Of Ophthalmology*. 2009. Volume 148 : 221-226
16. Basu S. Novel CycloOxygenase-Catalized Bioactive Prostaglandin F_{2α} From Physiology to New Principles in Inflammation. *Medical Research Review*. 2007. Vol 27 (4) : 435-468
17. Guglielminetti E, Barabino S, Monaco M, Montero S, Rolando M. HLA-DR Expression in Conjunctival Cell After Latanaprost. *Journal of Ocular Pharmacology and Therapeutics*. 2002 Volume 18 (1) : 1-9
18. Rodrigues MV, Crosta FD, Soares, CP, DeghaideNHS, Duarte R, Sakamoto F, Futrado JMF, Paula JS, Donadi EA, Soares EG. Immunohistochemical Expression of HLA-DR in Conjunctiva of Patients Under Topical Prostaglandin Analogs Treatment. *Journal Of Glaucoma*. 2009. Volume 18(3) : 197-200
19. Huang LC, Wong JR, Llmazares JA, Nousari CH, Perez VL, Amescua G, Karp CL, Galor A. Pseudopemphigoid as Caused by Topical Drugs And Pemphigus Disease. *World Journal Of Ophthalmology*. 2015. Volume 5(1) : 1-15
20. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of Ocular Symptoms and Sign with Preserved and Preservative Free Glaucoma Medication. *British Journal of Ophthalmology*. 2002. Volume 86 : 418-423
21. Kashkouli MD, Beigi B, Murthy R, Astbury N. Acquired External Punctal Stenosis : Etiology and Associated Findings. *American Journal of Ophthalmology*. 2003. Volume 136 (6) : 1079-1084
22. Thorne JE, Anhalt GJ, Jabs DA. Mucous Membrane Pemphigoid And Pseudopemphigoid. *Ophthalmology*. 2004. Volume 111 :45-52 [PMID: 14711713 DOI: 10.1016/j.optha.2003.03.001]
23. Bukhari A. Prevalence of Punctal Stenosis Among Ophthalmology Patient. *Middle East African Journal of Ophthalmology*. 2009. Volume 16 (2) : 85-87
24. Ulusoy MO, Atakan M, Kivanc SA. Prevalence and Associated Factors of External Punctal Stenosis Among Elderly Patients in Turkey. *Arquivos Brasileiros De Oftalmologia*. 2017. Volume 80 (5) : 269-299
25. Cantor LB, Rapuano JC, Cioffi GA. Development, Anatomy, and Physiology of the Lacrimal Secretary and Drainage Systems. *Basic and Clinical Science Course- Section7 : Orbit, Eyelids, and Lacrimal System*. Singapore. American Academy of Ophthalmology; 2014 : 243-247.
26. Kanski JJ. Lacrimal Drainage System. *Kanski Clinical Ophthalmology: A Systemic Approach*. Philadelphia: Elsevier; 2007. p. 151-164.
27. Kakizaki H. Anatomy, Physiology, and Immunology of the Lacrimal System. In Ali MJ (ed) *Principle and Practice of Lacrimal Surgery*.New Delhi. Springer.2015 : 17-34
28. Isloor SD. Surgical Anatomy of the Lacrimal Excretory System and Lateral Wall of the Nose. In Isloor SD (ed). *Lacrimal Drainage Surgery*. Jaypee Pub. New Delhi. 2014 : 3-9
29. Dudeja G, Khazai HM, Shetty KB, Khurana BP. Recent Advances in Management of Acquired Punctal Stenosis. *Delhi Journal of Ophthalmology*. 2015. Volume 26 (2) : 118-124

30. Daniel P. Schaefer. Acquired Etiologies of Lacrimal System Obstructions. In Cohen A, Mercandetti M, Brazzo B (eds). *The Lacrimal System: Diagnosis, Management and Surgery* Springer. New York; 2009:43-65.
31. Hur MC, Jin SW, Roh MU, Jeong JW, Ryu WY, Kwon YH, Ahn HB. Classification of Lacrimal Punctal Stenosis and Its Relates Histopatological Feature in Patients With Epiphora. *Korean Journal Of Ophthalmology*. 2017. Volume 31 (5) : 375-382
32. Bukhari AA. Management Option of Punctal Stenosis. *Saudi Medical Journal*. 2013. Volume 34 (8) : 785-792
33. Kashkouli MB, Pakdel F, Kiavash V. Assessment and Management of Proximal and Incomplete Symptomatic obstruction of the Lacrimal System. *Middle East African Journal of Ophthalmology*. 2012. Volume 19 (1) : 60-67
34. Kashkouli MB, Nilforushan N, Nojomi N, Rezaee R. External Lacrimal Punctum Grading : Realibility and Interobserver Variation. *European Journal of Ophthalmology*. 2008. Volume 18 (4) : 507-511
35. Komínek P, Della Rocca RC, Rosenbaum S. Diagnostics. In: Weber RK, Keerl R, Schaefer SD, Della Rocca RC (eds). *Atlas of Lacrimal Surgery*: Springer Berlin Heidelberg; 2007 : 29-51.
36. Sklar. *Ophthalmic Product : Bowman Lacrimal Probe*(online). Available from : [www. Sklarcorp.com](http://www.Sklarcorp.com) Diakses pada tanggal 20 Januari 2018.
37. Grover AK, Baruah R. Evaluation of Epiphora. In Nema HV, Nema N (eds) *Diagnostic Procedures in Ophthalmology*. Second Edition. New Delhi. Jaypee Brother Medical Pub. 2009 : 412-425
38. Das S. Evaluation of Epiphora. In Ali MJ (ed) *Principle and Practice of Lacrimal Surgery*. New Delhi. Springer. 2015 :61-74
39. Esmaeli B, HortoBagyi G, Esteva F, Valera V, Ahmadi MA, Booser D, Ibrahim N, Delpassand E, Arbuckle R. Canalicular Stenosis Secondary to Weekly Docetaxel : a Potentially Preventable Side Effect. *Annalas of Oncology*. 2002. Volume 13 : 218-221
40. Esmaeli B, Amin S, Valero V, Adinin R, Arbuckle R, Banay R, Do KA, Rivera E. Prospective Study of Incidence and Severity of Epiphora and Canalicular Stenosis in Patients, with Metastatic Breast Cancer Receiving Docetaxel. *Journal Of Clinical Oncology*. 2006. Volume 24 (22) : 3619-3622
41. Philpott C, Yung MW. Proximal Lacrimal Obstruction : A Review. *European Ophthalmic Review*. 2009. Volume 3(1):81-84
DOI: <http://doi.org/10.17925/EOR.2009.03.01.81>
42. Carter KD, Nelson CC, Martonyi CL. Size Variation of Lacrimal Punctum in Adults. *Ophthalmic Plastic and Reconstructive Surgery*. 1988. Volume 4 (\$) : 231-233.
43. Woog JJ. The Incidence Of Symptomatic Acquired Lacrimal Outflow Obstruction Among Residents OF Olmsted County Minnesota, 1976-2000(An American Ophthalmological Society Thesis). *Trans American Ophthalmology Society*. 2007 Volume 105 : 649-666
44. Yoon KC, Jeong SK, Park YG. Study Of Lacrimal Punctal Size In Normal Adults. *Journal of Korean Ophthalmology Society*. 1997. Volume 38: 1916-1920.

45. Isloor SD. Physiology of the Lacrimal System. In Isloor SD (ed). *Lacrimal Drainage Surgery*. Jaypee Pub. New Delhi. 2014 : 10-11
46. Cunsolo M, Cigarini E, Menichetti M. Physiology of The Lacrimal Drainage System. In Presutti L, Mattioli F(eds) *Endoscopic Surgery of The Lacrimal System*. Modena Italy. Springer. 2016 : 19-22
47. Murgatroyd H, Craig JP, Sloan B. Determination of Relative Contribution of the Inferior Canaliculi to The Lacrimal Drainage System in Health Using The Drop Test. *Clinical and Experimental Ophthalmology*. 2004. Volume 32 : 404-410.
48. Kashkouli MB, Pakdel F, Hashemi M, Ghaempanah MJ, Rezaee R, Kagnaz-Kanani R, Ahadian A. Comparing Anatomical Pattern of Topical Anti-Glaucoma Medication Associated Lacrimal Obstruction With a Control Group. *Orbit*. 2010. Volume 29 (2) : 65-69
49. Ortiz-Basso T, Galmarini A, Luis Vigo R, Gonzalez- Barlalay JM, Premoli EJ. The Relationship Between Topical Anti Glaucoma Medication and The Development of Lacrimal Drainage System Obstruction. *Arquivos Brasileiros De Oftalmologia*. 2018. Volume 81 (6) 490-493.
50. Basu S. Bioactive Eicosanoids : Role of Prostaglandin F_{2α} and F₂-Isoprostanes in Inflammation and Oxidative Stress Related Pathology. *Molecules and Cell*. 2010. Volume 30 : 283-391
51. Society EG. European Glaucoma Society Terminology and Guidelines for Glaucoma. 4th Edition - Chapter 3: Treatment principles and options. *bjophthalmol*. 2016:1-72
52. South East Asia Glaucoma Interest Group. *Asia Pacific Glaucoma Guideline*. Sydney. Scientific Communication of SEAGIG.org. 2008
53. Mastropasqua L, Agnifili L, Mastropasqua R, Fasanella V. Conjunctival Modification Induced by Medical and Surgical Therapies in Patients With Glaucoma. *Current Opinion in Pharmacology*. 2013. Volume 13 : 56-64
54. Zhu W, Kong X, Xu J, Sun X. Effects of Long term Anti Glaucoma Eyedrop on Conjunctival Structure : an In Vivo Confocal Microscopy Study. *Journal Of Ophthalmology*. 2015 : 1-7
55. Demirel S, Doganay S, Gurses I, Iraz. Toxic-Inflammatory Effects of Prostaglandin Analogues on the Ocular Surface. *Ocular Immunology and Inflammation*, 2013. Volume 21 (6) : 6-11
56. Abbas K, Mitchell F. *Robbins Basic Pathology*. 8th Edition. UK. Elsevier : 2007
57. Ueha S, Shand FHW, Matsushima K. Cellular and Molecular Mechanism of Chronic Inflammation- Associated Organ Fibrosis. *Frontiers in Immunology*. 2012. Volume 3 (71) : 1-6
58. Butt Z, Kaufman D, Mc Nab A, Mc Kelvie P. Drug-Induced Ocular Cicatricial Pemphigoid : a Series of Clinico-Pathological Reports. *Eye*. 1998. Volume 12 : 285-290
59. Irkec M. Do We Really Need Preservatives For Efficacy Of Glaucoma Medications? Ditampilkan pada 47 th Panhellenic Ophthalmology Congress. Thessaloniki. 2014
60. Baudouin C. Detrimental Effect of Preservative in Eyedrops : Implication for The Treatment of Glaucoma. *Acta Ophthalmology*. 2008. Volume 86 : 716-726
61. Kaur IP, Lal S, Rana C, kakkar S, Singh H. Ocular Preservative : Associated Risk and Newer Options. *Cutaneous and Ocular Toxicology*. 2009. Volume 28 (3) : 93-103

62. Weston BC, Loveless JW. Canalicular Stenosis Due to Topical Use of Fortified Antibiotics. *Canada Journal of Ophthalmology*.2000. Volume 35 (6) : 334-335
63. Cantor LB, Rapuano CJ, Cioffi GA. Introduction to Galucoma : Terminology, Epidemiology and Heredity. *Basic and Clinical Science Course- Section10 : Glaucoma*. Singapore. American Academy of Ophthalmology; 2014 : 3-12.
64. Ilahi F, Vera. Tampilan Klinis pada Glaukoma Primer Sudut Terbuka di RSUP DR. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 2018. Vol 7 (1) : 1-4
65. Vitresia H. Profil Glaukoma di Provinsi Sumatera Barat Indonesia. Thesis. Bagian Ilmu Kesehatan Mata / Program Pendidikan Dokter Spesialis Ilmu Kesehatan Mata. Padang. 2008
66. Morel MD. Side Effects of Glaucoma Medication. *Bull Soc Belge Ophthalmology*. 2006. Volume 299 : 27-40
67. Ishibashi T, Yokoi N, Kinoshita S. Comparison of The Short Term Effects on the Human Corneal Surface of Topical Timolol Maleate With and Without Benzalkonium Chloride. *Journal of Glaucoma*. 2003. Vol 12 (6) : 486-490

